Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Third Harmonic Bio, Inc.

Get SEC filing alerts via email and in your feed for Third Harmonic Bio, Inc.

THRD

Third Harmonic Bio, Inc.

About Third Harmonic Bio, Inc.

Third Harmonic Bio is a biopharmaceutical company developing oral, highly selective KIT inhibitors to treat mast cell-driven inflammatory diseases such as chronic spontaneous urticaria. Its lead candidate, THB335, aims to provide a convenient, targeted therapy with potential applications across skin, respiratory, and gastrointestinal conditions. The company focuses on innovative drug development, leveraging proprietary technology and strategic licensing to address unmet medical needs in allergy and inflammation.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Third Harmonic Bio, Inc.

1
1
Third Harmonic Bio, Inc. Third Harmonic Bio Reports $15.8 Million Net Loss, Announces Plan of Dissolution

Via official filing (AI summary) | about 1 year ago | 0 comments

2
1
Third Harmonic Bio, Inc. Third Harmonic Bio Reports $45.5 Million Net Loss for 2024, Announces Restructuring and THB335 Clinical Trial Results

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
Third Harmonic Bio, Inc. Third Harmonic Bio Reports Financial Results, Advances Lead Product Candidate THB335

Via official filing (AI summary) | over 1 year ago | 0 comments